Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan

Medical Mycology

Volumn 47, Issue 2, 2009, Pages 145-148

  Ikeda, Fumiaki ^a   Saika, Takeshi ^a   Sato, Yumie ^a   Suzuki, Makoto ^a   Hasegawa, Miyuki ^a   Mikawa, Takashi ^a   Kobayashi, Intetsu ^b   Tsuji, Akiyoshi ^b  

^a LSI MEDIENCE CORPORATION   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antifungal agent; Aspergillus; Candida; In vitro susceptibility; Pediatric patient

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PEDIATRICS;

ADOLESCENT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; JAPAN; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 59249087161     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802262123     Document Type: Article

References (13)

1. Hatano, K., Morishita, Y. Nakai, T. et al. (2002) Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo), 55, pp. 219-222.
2. Clinical and Laboratory Standards Institute (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts
3. Bartizal, C. and Odds, FC. (2003) Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother, 47, pp. 2100-2107.
4. Odds, FC, Motyl, M. Andrade, R. et al. (2004) Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol, 42, pp. 3475-3482.
5. Pfaller, MA, Boyken, L. Hollis, RJ et al. (2006) Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol, 44, pp. 3533-3538.
6. Pfaller, MA, Boyken, L. Hollis, RJ et al. (2008) In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance. J Clin Microbiol, 46, pp. 150-156.
7. Ostrosky-Zeichner, L., Rex, JH Pappas, PG et al. (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother, 47, pp. 3149-3154.
8. Clinical and Laboratory Standards Institute (2002) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi
9. Tawara, S., Ikeda, F. Maki, K. et al. (2000) In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother, 44, pp. 57-62.
10. Arikan, S., Yurdakul, P. and Hascelik, G. (2003) Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob Agents Chemother, 47, pp. 2640-2643.
11. de Wet, NA, Llanos-Cuentas, J. Suleiman, E. et al. (2004) A randomized, double blind, parallel group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis, 39, pp. 842-849.
12. Kohno, S., Masaoka, T. Yamaguchi, H. et al. (2004) A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis, 36, pp. 372-379.
13. Hope, WW, Seibel, NL Schwartz, CL et al. (2007) Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother, 51, pp. 3714-3719.